NCT06090331No Longer Available不适用
An Expanded Access Program for the Non-invasive Detection of Clear Cell Renal Cell Carcinoma (ccRCC) in Patients With Renal Masses Utilizing 89Zirconium-labelled Girentuximab (89Zr-DFO-girentuximab)
Telix Pharmaceuticals (Innovations) Pty Limited39 个研究点 分布在 1 个国家开始时间: 2023年10月19日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 发起方
- 试验地点
- 39
研究概览
简要总结
The purpose of this Expanded Access Program (EAP) is to enable the use of 89Zr-DFO-girentuximab with positron emission tomography/computed tomography (PET/CT) imaging to non-invasively detect carbonic anhydrase 9 (CAIX)-expressing clear cell renal cell carcinoma (ccRCC) in patients with renal masses as determined by conventional imaging.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written and voluntarily given informed consent.
- •Male or female ≥ 18 years of age.
- •Imaging evidence of renal mass(es) obtained from conventional diagnostic imaging with CT or MRI (without and with contrast enhancement) based on national standards that is not older than 90 days on Day 0, and that was performed before any screening procedure.
- •Negative urine/serum pregnancy tests in female patients of childbearing potential.
- •Consent to practice highly effective contraception until a minimum of 42 days after IV 89Zr-DFO-girentuximab administration.
排除标准
- •Renal mass known to be a metastasis of another primary tumor.
- •Active non-renal malignancy requiring therapy during and up to EOT visit.
- •Radiotherapy or immunotherapy within 4 weeks (28 days) prior to the planned administration of 89Zr-DFO-girentuximab or continuing adverse effects (> grade 1 using Common Terminology Criteria for Adverse Events [CTCAE] version 5.0) from such therapy.
- •Planned antineoplastic therapies (for the period between IV administration of 89Zr-DFO-girentuximab and imaging).
- •Previous administration of any radionuclide within 10 of its half-lives before Day
- •Serious non-malignant disease (e.g., psychiatric, infectious, autoimmune, or metabolic), that may interfere with the objectives of the program or with the safety or compliance of the subject, as judged by the Investigator.
- •Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the program.
- •Exposure to any experimental diagnostic or therapeutic drug within 30 days from the date of planned administration of 89Zr-DFO-girentuximab.
- •Women who are pregnant or breastfeeding.
- •Known hypersensitivity to girentuximab or DFO (desferoxamine).
研究者
研究点 (39)
Loading locations...
相似试验
No Longer Available
不适用
18F-Floretyrosine Expanded Access ProgramGlioma (Any Grade) in the BrainNCT06743100Telix Pharmaceuticals (Innovations) Pty Limited
No Longer Available
不适用
Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)Multiple System Atrophy (MSA)NCT05086094Biohaven Pharmaceuticals, Inc.
No Longer Available
不适用
Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple SclerosisMultiple SclerosisNCT02807285Genentech, Inc.
No Longer Available
不适用
Expanded Access to Rovalpituzumab TesirineSmall Cell Lung CancerNCT03503890AbbVie
Available
不适用
Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221GBMGlioblastoma MultiformeNCT02146066Northwest Biotherapeutics